Marked dissociation between intracellular Ca2+ level and contraction on exposure of rat aorta to lysophosphatidylcholine

European Journal of Pharmacology

Volumn 378, Issue 2, 1999, Pages 177-186

  Suenaga, Hiroshi ^a   Kamata, Katsuo ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

Aorta, rat; Ca2+ level, cytosolic; Contraction; Detergent; Lysophosphatidylcholine

Indexed keywords

LYSOPHOSPHATIDYLCHOLINE;

ANIMAL TISSUE; AORTA; ARTICLE; CALCIUM CELL LEVEL; CONTROLLED STUDY; ENDOTHELIUM; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; VASOCONSTRICTION;

ANIMALS; AORTA, THORACIC; CALCIUM; CYCLIC AMP; CYCLIC GMP; DOSE-RESPONSE RELATIONSHIP, DRUG; ISOMETRIC CONTRACTION; LYSOPHOSPHATIDYLCHOLINES; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; PROTEIN KINASE C; RATS; RATS, WISTAR;

EID: 0032788721     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00458-6     Document Type: Article

References (43)

1. Abe F., Mitsui M., Karaki H., Endoh M. Calcium compartments in vascular smooth muscle cells as detected by aequorin signal. Br. J. Pharmacol. 116:1995;3000-3004.
2. Abe F., Karaki H., Endoh M. Effects of cyclopiazonic acid and ryanodine on cytosolic calcium and contraction in vascular smooth muscle. Br. J. Pharmacol. 118:1996;1711-1716.
3. Asaoka Y., Nakamura S., Yoshida K., Nishizuka Y. Protein kinase C, calcium and phospholipid degradation. Trends Biol. Sci. 17:1992;414-417.
4. 2+ measured with fura-2. Br. J. Pharmacol. 104:1991;373-378.
5. Bazan E., Campball A.K., Rapoport R.M. Effects of phorbol esters on contraction and protein kinase C activation in rabbit aorta. Life Sci. 54:1993;29-33.
6. Bells R.M., Burns D.J. Lipid activation of protein kinase C. J. Biol. Chem. 266:1991;4661-4664.
7. Bergmann S.R., Ferguson T.B. Jr., Sobel B.E. Effects of amphiphiles on erythrocytes, coronary arteries, and perfused hearts. Am. J. Physiol. 240:1981;H229-H237.
8. 2+ influx, enhanced DNA synthesis and cytotoxicity in cultured vascular smooth muscle cells. Atherosclerosis. 112:1995;69-76.
9. 2+-overload induced by lysophosphatidylcholine in rat isolated cardiomyocytes. Br. J. Pharmacol. 118:1996;865-870.
10. Corr P.B., Snyder D.W., Lee B.I., Gross R.W., Keim C.R., Sobel B.E. Pathophysiological concentration of lysophosphatides and the slow response. Am. J. Physiol. 243:1982;H187-H195.
11. Corr P.B., Greer R.W., Sobel B.E. Amphipathic metabolites and membrane dysfunction in ischemic myocardium. Circ. Res. 55:1984;136-154.
12. Danthuluri N.R., Deth R.C. Phorbol ester-induced contraction of arterial smooth muscle and inhibition of α-adrenergic response. Biochem. Biophys. Res. Commun. 125:1984;1103-1109.
13. Das D.K., Engelman R.M., Rousou J.A., Breyer R.H., Otani H., Lemeshow S. Role of membrane phospholipids in myocardial injury induced by ischemia and reperfusion. Am. J. Physiol. 251:1986;H71-H79.
14. Flavahan N.A. Atherosclerosis of lipoprotein-induced endothelial dysfunction: potential mechanisms underlying reduction in EDRF/nitric oxide activity. Circulation. 85:1992;1927-1937.
15. Goldstein D.A. Calculation of the concentrations of free cations and cation-ligand complexes in solutions containing multiple divalent cations and ligands. Biophys. J. 26:1979;235-242.
16. Ishida H., Hirota Y., Nakazawa H. Effect of sub-skinning concentrations of saponin on intracellular Ca2+ and plasma membrane fluidity in cultured cardiac cells. Biochim. Biophys. Acta. 1145:1993;58-62.
17. Itoh H., Lederis K. Contraction of rat thoracic aorta strips induced by phorbol 12-myristate 13-acetate. Am. J. Physiol. 252:1987;C244-C247.
18. 2+ sensitivity in α-toxin-permeabilized small mesenteric artery from the rat. Br. J. Pharmacol. 117:1996;1238-1244.
19. Karaki H., Sato K., Ozaki H., Murakami K. Effects of sodium nitroprusside on cytosolic calcium level in vascular smooth muscle. Eur. J. Pharmacol. 156:1988;259-266.
20. Karaki H., Ozaki H., Hori M., Mitsui-Saito M., Amano K., Harada K., Miyamoto S., Nakazawa H., Won K.J., Sato K. Calcium movements, distribution, and functions in smooth muscle. Pharmacol. Rev. 49:1997;157-230.
21. Kinnaird A.A.A., Choy P.C., Man R.Y.K. lysophosphatidylcholine accumulation in the ischemic canine heart. Lipids. 23:1988;32-35.
22. 2+ level from myosin light chain phosphorylation and contraction in rat aorta. Br. J. Pharmacol. 118:1996;543-548.
23. Kugiyama K., Kerns S.A., Morrisett J.D., Roberts R., Henry P.D. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature. 344:1990;160-162.
24. Kugiyama K., Ohgushi M., Sugiyama S., Murohara T., Fukunaga K., Miyamoto E., Yasue H. Lysophosphatidylcholine inhibits surface receptor-mediated intracellular signals in endothelial cells by a pathway involving protein kinase C activation. Circ. Res. 71:1992;1422-1428.
25. Liu E., Goldhaber J.I., Weiss J.N. Effects of lysophosphatidylcholine on electrophysiological properties and excitation-contraction coupling in isolated guinea-pig ventricular myocytes. J. Clin. Invest. 88:1991;1819-1832.
26. Locher R., Weisser B., Mengden T., Brunner C., Vetter W. Lysolecithin action on vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 183:1992;156-162.
27. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
28. Murohara T., Kugiyama K., Ohgushi M., Sugiyama S., Ohta Y., Yasue H. LPC in oxidized LDL elicits vasocontraction and inhibits endothelium-dependent relaxation. Am. J. Physiol. 267:1994;H2441-H2449.
29. Nishizuka Y. Studies and perspectives of protein kinase C. Science. 233:1986;305-312.
30. Portman O.W., Soltys P., Alexander M., Osuga T. Metabolism of lysolecithin in vivo: effects of hyperlipemia and atherosclerosis in squirrel monkeys. J. Lipid Res. 11:1970;596-604.
31. Rajavashisth T.A., Andalibi A., Territo M.C., Berliner J.A., Navab M., Fogelman M.A., Lusis A.J. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature. 344:1990;254-257.
32. Rasmussen H., Forder J., Kojima I., Scriabine A. TPA-induced contraction of isolated rabbit vascular smooth muscle. Biochem. Biophys. Res. Commun. 122:1984;776-784.
33. Rasmussen H., Takuwa Y., Park S. Protein kinase C in the regulation of smooth muscle contraction. FASEB J. 1:1987;177-185.
34. Sato K., Ozaki H., Karaki H. Changes in cytosolic calcium level in vascular smooth muscle strip measured simultaneously with contraction using fluorescent calcium indicator fura-2. J. Pharmacol. Exp. Ther. 246:1988;294-300.
35. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol, modifications of low-density lipoprotein that increase its atherogenicity. New Engl. J. Med. 320:1989;915-924.
36. 2+ influx in vascular smooth muscle cells. Am. J. Physiol. 264:1993;C885-C893.
37. 2+ in rat aorta. Eur J. Pharmacol. 361:1998;217-226.
38. Suenaga H., Kamata K., Kasuya Y. Phorbol ester (PMA)-induced biphasic contraction of the rat aorta and effects of sodium nitroprusside and forskolin on the contraction. Res. Commun. Chem. Pathol. Pharm. 79:1993;313-324.
39. Tokumura A., Iimori M., Nishioka Y., Kitahara M., Sakashita M., Tanaka S. Lysophosphatidic acids induce proliferation of cultured vascular smooth muscle cells from rat aorta. Am. J. Physiol. 267:1994;C204-C210.
40. 2+-overload in isolated cardiomyocytes and effect of cytoprotective drugs. J. Mol. Cell. Cardiol. 24:1992;977-988.
41. Vidaver G.A., Ting A., Lee J.W. Evidence that lysolecithin is an important causal agent of atherosclerosis. J. Theor. Biol. 115:1985;27-41.
42. Witztum J.L., Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest. 88:1991;1785-1792.
43. Wrobleski I., LaDue J.S. Lactic dehydrogenase activity in blood. Proc. Soc. Exp. Biol. Med. 90:1955;210-213.